

THROUGH COURIER/FAX – 022-26598237, 26598238

FHL/SEC/S-2/AR/2010-11
March 14, 2011

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra – Kurla Complex,
Bandra (East),
Mumbai - 400051

Sub: Press Release


Dear Sirs,

Fortis Healthcare (India) Limited and TotipotentRX Cell Therapy Pvt. Ltd, a leading provider of cutting-edge technologies in the stem cell and regenerative medicine market, announced a collaboration to set up centres of excellence offering cellular therapies and stem cell clinical trials, across select Fortis hospitals.

A copy of Press Release, being issued by the Company in this regard, is enclosed for your reference and records please.

Thanking you,

Yours faithfully,
for Fortis Healthcare (India) Limited




Ruchi Mahajan
Company Secretary

Encl: As above

PRESS RELEASE

Fortis Healthcare ties up with TotipotentRX to set up Stem Cell Therapy Centres

New Delhi, March 14, 2011: Fortis Healthcare (India) Ltd, India's fastest growing hospital network and TotipotentRX Cell Therapy Pvt. Ltd, a leading provider of cutting-edge technologies in the stem cell and regenerative medicine market, announced a collaboration to set up centres of excellence offering cellular therapies and stem cell clinical trials, across select Fortis hospitals. These centres will undertake stem cell clinical research procedures relating to diabetes, cancer, cardiovascular disease, and neurological ischemia. TotipotentRX will also set up state-of-the-art cGMP laboratories in select hospitals, for processing stem cells before transplantation to patients.

Fortis Healthcare and TotipotentRX will leverage Fortis' hospital network and respective areas of clinical expertise to investigate new regenerative therapies, using promising adult stem cell sources like cord blood, bone marrow, and adipose tissue. As part of the alliance, a Stem Cell Medical Board will be created to oversee the medical research programme, ensure execution and monitor the progress following International and Indian ethical guidelines. The board will also impart training and create awareness around the benefits of stem cell therapy across India.

Speaking about the partnership, Shivinder Mohan Singh, Managing Director, Fortis Healthcare (India) Limited, said, "This tie-up allows Fortis to partner with the finest in the field of stem cell therapy and lead the way in this specialized new treatment modality, acknowledged to be at the cutting edge of modern medicine. This is in continuation of our effort to bring the latest in medicine to our customers, in a caring environment and at affordable prices. We will continue to pursue our vision of clinical excellence, with a focus on distinctive patient care."

In the words of Kenneth Harris, CEO, TotipotentRX (MK Alliance Inc.), "We are excited to partner with the established pan-India hospital network of Fortis Healthcare and this collaboration allows us to carry out advanced clinical research, aimed at addressing quality of life improvements for several healthcare challenges in India."

Stem Cell therapy is widely recognised to be the future of medicine due to its proven ability to repair and regenerate damaged and diseased organs and tissues. According to available literature, stem cell therapy is being used to treat diseases like peripheral arterial disease (PAD), chronic heart failure, and prostate cancer.





About Fortis Healthcare (India) Limited

Fortis Healthcare (India) Limited is committed to clinical excellence and patient-centric healthcare, which is manifest in hospital design, patient services, medical programmes and the compassionate approach of medical and non-medical hospital staff. Fortis commissioned its first hospital in 2001 at Mohali, near Chandigarh, and has expanded its operations to become a network with around 8000 bed capacity across 55 hospitals (includes 7 projects in pipeline). The Fortis network has a large number of international accreditations, including four JCI (Joint Commission International) and seven NABH (National Accreditation Board for Hospitals) certifications. The network's capability covers multi-speciality hospitals and super-speciality centres that provide tertiary and quaternary healthcare to patients in the major medical specialities.

About TotipotentRX

TotipotentRX Cell Therapy Pvt. Ltd., a subsidiary of TotipotentRX Corporation (MK Alliance Group company), is the leading vertically integrated regenerative medicine service and technology organization supporting institutions in the development, processing and clinical adoption of cell-based therapies. Their capabilities fulfil clinical and research needs from bench to bedside using laboratory cGMP/GTP/GLP standards and proprietary point-of-care tools and technologies for the clinical cellular therapy market. Toti is headquartered in Los Angeles, California with subsidiaries in New Delhi/Gurgaon and Mumbai India.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

For further details please contact:


Ranjana Smetacek / Ruhee Dhar
Fortis Healthcare (India) Ltd
9958999840 / 9818102377

Gaurav Chugh / Pawanpreet Singh
Fortis Healthcare (India) Limited
9958588900

Deba Sahoo
Hanmer MSL Delhi
9312832228

Hiren Shah/Sahana Chowdhury
Hanmer MSL Mumbai
9820384223 / 9892826469

Certified True Copy
For Fortis Healthcare (India) Limited


Company Secretary